We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+19.03%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$4.08B
AUM Growth
+$976M
Cap. Flow
+$264M
Cap. Flow %
6.47%
Top 10 Hldgs %
75.07%
Holding
69
New
11
Increased
11
Reduced
6
Closed
16

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$97.8M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$85.3M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$61.7M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$49.6M
5
RVMD icon
Revolution Medicines
RVMD
+$45.3M

Top Sells

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$45.3M
2
KYMR icon
Kymera Therapeutics
KYMR
+$23.6M
3
ACET icon
Adicet Bio
ACET
+$20.5M
4
DYN icon
Dyne Therapeutics
DYN
+$18M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 92.91%
2 Miscellaneous 7.09%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
1
Prothena Corp
PRTA
$479M
$791M 19.38%
11,584,280
– –
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
$497M 12.17%
5,451,647
– –
SRPT icon
3
Sarepta Therapeutics
SRPT
$2.2B
$419M 10.27%
3,660,798
+661,345
+22% +$85.3M
JNJ icon
4
CALL
Johnson & Johnson
JNJ
$646B
$281M 6.89%
+1,700,000
New +$274M
LKFT
5
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$234M 5.73%
5,756,268
+1,511,623
+36% +$61.7M
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$221M 5.4%
3,846,964
-2
-0% -$104
RVMD icon
7
Revolution Medicines
RVMD
$44.6B
$193M 4.72%
7,198,700
+1,846,517
+35% +$45.3M
ANAB icon
8
AnaptysBio
ANAB
$1.67B
$153M 3.75%
7,521,024
– –
ACAD icon
9
Acadia Pharmaceuticals
ACAD
$5.02B
$143M 3.52%
5,991,479
– –
XNCR icon
10
Xencor
XNCR
$1.94B
$132M 3.23%
5,282,516
– –
ZYME icon
11
Zymeworks
ZYME
$2.02B
$116M 2.84%
13,437,473
+3,350,000
+33% +$30M
BPMC
12
DELISTED
Blueprint Medicines
BPMC
$114M 2.78%
+1,798,300
New +$97.8M
ARVN icon
13
Arvinas
ARVN
$600M
$99.7M 2.44%
4,017,788
+300,000
+8% +$7.72M
SWTX
14
DELISTED
SpringWorks Therapeutics
SWTX
$90.7M 2.22%
3,460,208
– –
KURA icon
15
Kura Oncology
KURA
$1.13B
$61.4M 1.51%
5,806,871
-831,500
-13% -$9.83M
RLAY icon
16
Relay Therapeutics
RLAY
$4.11B
$52.3M 1.28%
4,163,824
– –
JAZZ icon
17
Jazz Pharmaceuticals
JAZZ
$15.9B
$45.7M 1.12%
+368,411
New +$49.6M
VYGR icon
18
Voyager Therapeutics
VYGR
$218M
$44.1M 1.08%
3,851,507
– –
CNTA
19
DELISTED
Centessa Pharmaceuticals
CNTA
$34.8M 0.85%
5,618,779
– –
EWTX icon
20
Edgewise Therapeutics
EWTX
$4.64B
$27.1M 0.66%
3,493,194
– –
ORIC icon
21
Oric Pharmaceuticals
ORIC
$1.37B
$26.5M 0.65%
3,418,068
– –
AVIR icon
22
Atea Pharmaceuticals
AVIR
$430M
$26.2M 0.64%
6,995,861
+811,000
+13% +$3.04M
NUVB icon
23
Nuvation Bio
NUVB
$2.34B
$25M 0.61%
13,896,543
– –
ALEC icon
24
Alector
ALEC
$261M
$24.4M 0.6%
4,056,548
– –
CRNX icon
25
Crinetics Pharmaceuticals
CRNX
$9B
$24M 0.59%
1,330,263
– –
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2023 Portfolio in Review

As of Q2 2023, EcoR1 Capital held 69 positions worth $4.08B, up 31% from $3.11B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

EcoR1 Capital deployed $264M of net new capital in Q2 2023, opening 11 new positions and adding to 11 existing holdings. Its largest new stake was Blueprint Medicines: 1,798,300 shares worth $114M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Janux Therapeutics, an estimated $45.3M trimmed.

  • EcoR1 Capital's largest Q2 2023 buy was Blueprint Medicines: 1,798,300 shares worth $114M.
  • EcoR1 Capital added most to Sarepta Therapeutics in Q2 2023, an estimated $85.3M increase.
  • EcoR1 Capital's biggest Q2 2023 reduction was Janux Therapeutics, cutting an estimated $45.3M.
  • EcoR1 Capital fully exited Kymera Therapeutics in Q2 2023, selling an estimated $23.6M.
  • EcoR1 Capital's ten largest holdings make up 75% of its $4.08B portfolio in Q2 2023.
  • EcoR1 Capital opened 11 new positions and closed 16 in Q2 2023.
  • EcoR1 Capital's portfolio value rose 31% quarter-over-quarter to $4.08B.

Based on EcoR1 Capital's 13F filing for Q2 2023, filed 14 Aug 2023.